Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04417803
Other study ID # ROSSI 2020
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 17, 2021
Est. completion date May 2028

Study information

Verified date February 2024
Source Centre Hospitalier Universitaire Dijon
Contact Olivier CASASNOVAS
Phone 0380295041
Email olivier.casasnovas@chu-dijon.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lymphomas are the most common haemopathic malignancy. The 3 most common types are diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma (HL) and follicular lymphoma (FL). In these three subtypes, the treatment strategy is most often curative. The therapeutic strategy is guided by PET (positron emission tomography), which optimises the risk-benefit balance between the efficacy and toxicity of the treatment and makes it possible to limit the intensity of treatment for good responders and to intensify the treatment of poor responders with a worse prognosis. PET therefore plays a central role in the pre-therapeutic evaluation of the disease and in the assessment of response to treatment. However, other complementary approaches could improve characterization prior to initiating lymphoma t-treatment and individual patient management during treatment and beyond. In DLBCL, it has been shown that the risk of relapse of good and bad responders is decreased by combining the PET response with a reduction in the amount of tumor DNA (ctDNA) in the blood, i.e. the genetic program of lymphoma cells that circulates freely in the blood. This evaluation of ctDNA has been made possible by the development of innovative techniques such as Next Generation Sequencing (NGS). In lymphomas, several approaches have been developed, the most sensitive and promising being CAPP-Seq (CAncer Personalized Profiling by deep Sequencing) developed at Stanford University. It is therefore useful to study the description of ctDNA in the 3 types of lymphomas and to analyse the progression profiles under treatment by trying to establish the major potential usefulness of these techniques: modifying treatment in case of poor response based on ctDNA +/- and PET, detecting relapses earlier than at present in patients without any other sign of relapse (clinical, blood or PET). The project presented here aims to build a collection of plasma samples taken before treatment, during treatment and during the first 2 years of follow-up in patients with one of the 3 most frequent types of lymphoma and undergoing curative treatment. The hypothesis is that sequential evaluation of ctDNA could improve the individualized management of future patients based on the results generated by the analyses of patients in this cohort.


Recruitment information / eligibility

Status Recruiting
Enrollment 900
Est. completion date May 2028
Est. primary completion date May 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Person who has not opposed to their inclusion in the trial - Confirmation of the diagnosis of one of the three lymphomas (DGLBL, LF or classic LH) according to the WHO 2016 international classification (Smerdlow et al, 2016) - Patients not currently taking treatment for their haemopathy (or who have received corticosteroid therapy alone within 14 days prior to the 1st sampling, dose limited to 500mg total) - Patients requiring systemic treatment within 30 days of screening - PET images available for pre-therapy and follow-up (mid-treatment, end of treatment) Exclusion Criteria: - Person subject to legal protection (curatorship, guardianship) - Person under partial judicial control - Pregnant, parturient or breastfeeding woman - Adult incapable or incapable of giving consent - Minor - Localized lymphoma treated by surgery and/or localized radiotherapy

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Blood sampling
plasmatic sampling

Locations

Country Name City State
France Chu Dijon Bourgogne Dijon

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary biomarkers identification of individual plasma biomarkers, based on cfDNA (cell-free DNA), by high-throughput sequencing of circulating ctDNA tumor DNA through study completion, an average of 7 years
Secondary tumour mutation profile Description of the tumour mutation profile using different molecular biology techniques (CAPP-seq, PHASE-seq, VIRCAPP-seq) by analysing circulating tumour DNA (ctDNA) from cfDNA through study completion, an average of 7 years
See also
  Status Clinical Trial Phase
Completed NCT01359982 - Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects Phase 1
Completed NCT02140736 - Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
Completed NCT00947739 - Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma Phase 1
Completed NCT00725634 - A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma Phase 1
Completed NCT00222443 - Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy Phase 1
Recruiting NCT02211755 - Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors Phase 1
Completed NCT02048488 - A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Recruiting NCT06148220 - A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors N/A
Completed NCT01031641 - Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing
Withdrawn NCT02786485 - Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT Phase 1
Completed NCT01387841 - Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting Phase 2
Completed NCT00396864 - Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma Phase 1
Terminated NCT00023166 - Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas Phase 1
Recruiting NCT05775406 - Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors Phase 1
Recruiting NCT02274584 - CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) Phase 1/Phase 2
Recruiting NCT01836822 - Bronchoscopic Sampling Techniques in Sarcoidosis N/A
Completed NCT02902237 - tTF-NGR Phase I Study Phase 1
Completed NCT02578316 - A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies. Phase 1
Recruiting NCT00900198 - Collection of Tissue Samples for Cancer Research
Completed NCT02740270 - Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas Phase 1